🔀 Bang Bang. Zoom Hit The Ground. Bang Bang. Bears Shot It DownZoom company's video-conferencing service became so ubiquitous during the Covid-19 pandemic that its corporate name became a verb describing the act of firing up a video chat to connect with coworkers online.
Zoom shares VIE:ZOOM rose seven-fold in 2020 as sales surged after millions of workers were stuck at home because of COVID-19 restrictions. By 2021, though, revenue growth slowed, and the stock plunged. The company has shed at least $100 billion in market value since then.
Meanwhile over the past two years, the stock has stagnated because Zoom's video-conferencing service is needed less as businesses continue pushing staff back to the office.
Zoom, one of the main enablers and beneficiaries of remote work, in August 2023 has asked its employees to head back to the office. The company announced that employees living within 50 miles of a Zoom office must work there at least two days a week.
"We believe that a structured hybrid approach – meaning employees that live near an office need to be onsite two days a week to interact with their teams – is most effective for Zoom," a spokesperson said in a statement. "As a company, we are in a better position to use our own technologies, continue to innovate, and support our global customers."
As pandemic Covid-19 is over, many other companies have announced return-to-office mandates, but Zoom's change of heart is surprising given the role its technology plays in remote work. The company's video-conferencing service became so ubiquitous during the pandemic that its corporate name became a verb describing the act of firing up a video chat to connect with coworkers online.
People are back to Travelling. The annual graph for NYSE:RPM , Revenue Passenger Miles for U.S. Air Carrier Domestic and International, Scheduled Passenger Flights.
Meanwhile, there're some important things to say.
Warren Buffett's 99-year-old business partner, Charlie Munger, was surprisingly embraced Zoom during the pandemic. Eric Yuan, the founder and CEO of the video-conferencing platform, celebrated the veteran investor's endorsement of his product on an earnings in 2021.
"I have fallen in love with Zoom," Munger, the vice-chairman of Berkshire Hathaway, said in a CNBC interview filmed at Berkshire's annual shareholder meeting in May, 2021.
"Zoom is here to stay. It just adds so much convenience."
• Munger added that he struck a deal in Australia using the communications tool. He trumpeted its prospects at Daily Journal's annual meeting in February, 2021 as well.
• When the pandemic is over, I don't think we're going back to just the way things were," the newspaper publisher's chairman said.
• We're going to do a lot less travel and a lot more Zooming.
Charlie loves Zoom and uses it frequently for business and to keep in touch with his family, as it's difficult for him to travel.
His business advice was to build a better product or offer a better solution, that it's all about competition, and that successful people are those with the acumen to understand life better than everyone else. He said it's up to you to work harder and better than the next person.
Charlie also said investments are better than money in the bank, and it's important to go to the office to work in person.
The main graph says, Zoom equities just hit the major all history ground support near $59 per share.
Covid19stock
Moderna's Surprising Profit Signals Post-Pandemic PivotModerna ( NASDAQ:MRNA ), the pioneering vaccine maker, reported a surprise fourth-quarter profit, sending ripples of optimism through the market. Bolstered by unexpected revenue and strategic cost-cutting measures, the company's resilience amid shifting tides in the pharmaceutical landscape has drawn both attention and applause.
Unveiling the Numbers:
Moderna's ( NASDAQ:MRNA ) fourth-quarter profit stood at a commendable $217 million, or 55 cents a share, defying analyst expectations of a substantial loss. This unexpected triumph was fueled by a combination of factors, including unforeseen deferred revenue and a strategic overhaul in manufacturing operations. The company's ability to navigate challenges and adapt swiftly underscores its agility and forward-thinking approach.
Navigating the COVID-19 Landscape:
While Moderna's COVID-19 vaccine continues to be its flagship product, generating substantial revenue, the company is strategically diversifying its portfolio. Despite a decline in COVID vaccine sales from 2022 to 2023, Moderna ( NASDAQ:MRNA ) remains steadfast in its commitment to innovation. The imminent approval decision for its respiratory syncytial virus (RSV) shot marks a significant milestone in this diversification strategy, offering a glimpse into the company's post-pandemic roadmap.
Looking Beyond COVID:
Moderna's ( NASDAQ:MRNA ) ambitious roadmap extends far beyond the realm of COVID-19. With plans to launch its RSV shot in key markets and a robust pipeline of experimental shots targeting influenza, cancer, and cytomegalovirus, the company is poised for a transformative journey. Despite concerns over efficacy declines compared to rival offerings, Moderna's ( NASDAQ:MRNA ) unwavering focus on research and development signals a bold leap into uncharted territories.
International Endeavors:
Moderna's ( NASDAQ:MRNA ) participation in the EU Health Emergency and Response Authority’s tendering procedure underscores its commitment to global health initiatives. By prioritizing key international markets and aligning with strategic partners, the company aims to broaden its reach and impact. The forthcoming decision on the EU tender is poised to shape the company's trajectory in the global arena, setting the stage for future collaborations and expansions.
Charting the Course Ahead:
As Moderna ( NASDAQ:MRNA ) reaffirms its 2024 forecast amidst shifting market dynamics, the company remains steadfast in its pursuit of excellence. With a projected $4 billion in sales and a focus on operational execution, Moderna ( NASDAQ:MRNA ) is poised to navigate challenges and seize opportunities in the years ahead.
Conclusion:
Moderna's ( NASDAQ:MRNA ) unexpected profit surge and strategic roadmap offer a compelling narrative of resilience and innovation in a rapidly evolving landscape. With eyes set on new horizons and a steadfast resolve, Moderna ( NASDAQ:MRNA ) emerges as a beacon of hope in the post-pandemic world.
PFE - BULLISH SCENARIOPfizer (NYSE:PFE) gained EU antitrust approval for its $43 billion acquisition of Seagen, a cancer drug maker. This acquisition, announced in March, is Pfizer's largest recent purchase, fueled by the financial success of its COVID-19 vaccines and treatments. The European Commission found no significant competition or pricing concerns in the 27-country European Union, stating that the merger doesn't raise competition issues.
Seagen, based in Washington, specializes in antibody-drug conjugates designed to selectively destroy cancer cells, sparing healthy ones.
Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
NVAX Novavax Vaccine approved! Buy Opportunity!If you haven`t bought NVAX during the pandemic:
Then you need to know that NVAX Novavax's recent achievements in gaining full marketing authorization for its COVID-19 vaccine, Nuvaxovid, in the UK and Singapore, alongside its availability in major U.S. pharmacies, have ignited optimism among investors. These milestones signify a bright future for NVAT stock.
The international authorization of Nuvaxovid opens doors to vast markets, enhancing revenue potential and global recognition for Novavax. the EU delayed the approval, but will update its decision by the end of this month.
Nuvaxovid's availability at CVS and Rite Aid in the U.S. immediately after regulatory clearance demonstrates its acceptance and accessibility.
Nuvaxovid is a protein-based COVID-19 vaccine, different from the mRNA vaccines of PFE and MRNA.
My price target is $10 by the end of this month.
Looking forward to read your opinion about it.
BionTech Fastly Approaching Major Resistance, Will we Break?Hi Guys, this is a Technical Analysis on BionTech (BNTX) on the 3 Day Timeframe.
We are currently approaching a MAJOR RESISTANCE Trendline.
This Trend started from the TOP in 08/2021.
Everytime we've interacted with it in the past, we've been REJECTED.
Will we get Rejected again?
Well, we've had 3 touch points already. In trendline theory, it states that atleast 3 touches are required before a trendline is weak enough to break through. So, it is possible that a break can occur.
With risk of new variants, hospitalizations of COVID increasing and a push of government to get people to get boosters, this could be a chance for Trend change to UPSIDE for BNTX.
BUT just looking at it in a pure TA lens, i wouldn't just start buying now.
I would wait for a break above the Trendline and CONFIRMATION above it.
Also with the break, note that VOLUME should be spiking and increasing.
We should not see a DECLINE in Volume as we break through.
That can be signs of a FAKEOUT.
We are also reaching some Resistance from a Support line turned Resistance line.
Now lets look at our indicators for more evidence.
RSI -> We've had the Lowest RSI reading on May 09,2023 EVER in BNTX history. This could be a catalyst for more buying pressure and a trend change. We also broke above RSI Red Resistance line.
MACD-> A momentum indicator, has crossed BULLISH, below the 0 level. If we continue this bullish momentum and the Blue/Orange lines move above the 0 level, this can be inject the well needed momentum for BNTX to increase in price.
STOCH RSI -> Is also in a BUllish cross and it shows that theres plenty of room for momentum to continue.
__________________________________________________________________________________
Thank you for taking the time to read my analysis. Hope it helped keep you informed. Please do support my ideas by boosting, following me and commenting. Thanks again.
Stay tuned for more updates on BNTX in the near future.
If you have any questions, do reach out. Thank you again.
DISCLAIMER: This is not financial advice, i am not a financial advisor. The thoughts expressed in the posts are my opinion and for educational purposes. Do not use my ideas for the basis of your trading strategy, make sure to work out your own strategy and when trading always spend majority of your time on risk management strategy.
AZN - BEARISH SCENARIOAstraZeneca's stock experienced a significant decline of over 4% on Monday due to uncertainties surrounding the future of CEO Pascal Soriot, as reported in the news. Initially, the company refrained from commenting on the report but later clarified that they do not engage in discussions regarding market rumors. Their shares, listed as NASDAQ: AZN, closed down 3.2%, marking the lowest point since July 19. Market analysts and a shareholder attributed this decline to the report, which indicated the possibility of Soriot leaving as soon as next year. Additionally, another article published on the same day discussed the retirement of Mene Pangalos, the long-time head of biopharmaceuticals research at AstraZeneca, although it appeared to present a contradictory view, quoting Pangalos as stating that Soriot had many productive years ahead of him.
This supports potential competition of head and shoulder formation to the mid-50s range.
BNTX: NICE BOTTOMING BASE ON THIS VACCINE PLAYBNTX (BioNTech) Healthcare sector
German company. Produce the BioNTech biotechnology. Partnership with Pfizer.
Nice long bottoming base since March.
Triple bottom .
It looks like a rectangle pattern .
All moving averages turning up .
A move above the blue zone (>195) could take it to 248 and maybe more.
I'm long with a stop at 165.
Trade safe!
Novavax: IT'S TIME TO GONovavax
Short Term - We look to Sell at 48.97 (stop at 53.42)
Prices expected to stall near trend line resistance. Trading volume is increasing. The trend of lower highs is located at 55.90. Preferred trade is to sell into rallies. A break of yesterdays low would confirm bearish momentum.
Our profit targets will be 22.96 and 13.90
Resistance: 50.00 / 63.00 / 100.00
Support: 41.00 / 23.12 / 15.00
Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
The 4 Kings of Glove: When Will They Reverse The Downtrend?Market Analysis
The 4 Kings are TOPGLOV, SUPERMX, KOSSAN & HARTA: (not to be confused with Andy Lau, Leon Lai, Aaron Kwok & Jacky Cheung)
Fundamental good stocks with strong revenue and cash positions. However, those that chase these heavily promoted stocks at the high side would really need to hold long term in order to recoup. Not sure when it will happen though.
Line chart shows the average price of all the 4 Kings.
So many bad/negative news (examples) despite good earnings drove the downtrend. Never fight the trend! nor matter what. When it rains, it pours like crazy...
1. Export got blocked by US custom borders for labor practices
2. Failing ASPs
3. Possible more windfall tax (not a really good idea as this will scare off future foreign investors to our country. They are legitimate business, no point to punish them for running a business and making a profit. Even though the profit is super bountiful due to covid19. Heck the glove industry already "donated" like RM500 million previously)
4. Closure of factories due to their workers getting infected by Covid19
5. More competition for folks that jump into glove making bandwagon (i think this will be a disaster for those new entrants once demand drops to pre-covid numbers. Just take a lesson from face masks. At one point, a box of face mask was selling up to RM50/70/100. Now, you can even buy a box at <RM5 at Shopee from China Sellers.)
6. Increase of raw material prices (latex and oil). Oil prices have been on a tear , but unfortunately our oil related counters are not trending upwards. (another story)
7. Heck even our EPF is borrowing out the shares for shorters (SBL).
8. The doctor or nurses do not use any glove when administrating vaccine to the general public (yes, i personally see this when taking the vaccine at PPV)
9. Whatever negative news that might churn out to explain the downtrend.
In the end : The markets are controlled by the big players.
Disclaimer
This information only serves as reference information and does not constitute a buy or sell call. Conduct your own research and assessment before deciding to buy or sell any stock
Moderna in trouble? Moderna
Short Term - We look to Sell at 149.49 (stop at 160.31)
Preferred trade is to sell into rallies. Closed below the 20-day EMA. Trades with a bearish descending triangle formation. Our overall sentiment remains bearish looking for lower levels. We look to set shorts in the early trade.
Our profit targets will be 123.84 and 103.50
Resistance: 150.00 / 171.76 / 187.50
Support: 125.00 / 120.00 / 104.00
Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
ALERS Cup & Handle BOALERS EUROBIO SCIENTIFIC is a company on the French stock market in the vitro medical diagnostics and also producing CAVID19 tests. It made a nice CUP & Handle BO with volume
EURONEXT:ALERS EURONEXT:ALERS ://www.tradingview.com/x/Uw1WlyDV/]https://www.tradingview.com/x/Uw1WlyDV/
Novavax Breaking Out? Novavax - Short Term - We look to Buy at 83.80 (stop at 75.92)
Price action has posted a bullish Engulfing Candle and is positive for short-term sentiment. We look for gains to be extended today. Short term oscillators have turned positive. Although the bears are in control, the stalling negative momentum indicates a turnaround is possible.
Our profit targets will be 101.48 and 112.00
Resistance: 90.00 / 100.00 / 140.00
Support: 70.00 / 60.00 / 50.00
Disclaimer – Saxo Bank Group. Please be reminded – you alone are responsible for your trading – both gains and losses. There is a very high degree of risk involved in trading. The technical analysis, like any and all indicators, strategies, columns, articles and other features accessible on/though this site (including those from Signal Centre) are for informational purposes only and should not be construed as investment advice by you. Such technical analysis are believed to be obtained from sources believed to be reliable, but not warrant their respective completeness or accuracy, or warrant any results from the use of the information. Your use of the technical analysis, as would also your use of any and all mentioned indicators, strategies, columns, articles and all other features, is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness (including suitability) of the information. You should assess the risk of any trade with your financial adviser and make your own independent decision(s) regarding any tradable products which may be the subject matter of the technical analysis or any of the said indicators, strategies, columns, articles and all other features.
Please also be reminded that if despite the above, any of the said technical analysis (or any of the said indicators, strategies, columns, articles and other features accessible on/through this site) is found to be advisory or a recommendation; and not merely informational in nature, the same is in any event provided with the intention of being for general circulation and availability only. As such it is not intended to and does not form part of any offer or recommendation directed at you specifically, or have any regard to the investment objectives, financial situation or needs of yourself or any other specific person. Before committing to a trade or investment therefore, please seek advice from a financial or other professional adviser regarding the suitability of the product for you and (where available) read the relevant product offer/description documents, including the risk disclosures. If you do not wish to seek such financial advice, please still exercise your mind and consider carefully whether the product is suitable for you because you alone remain responsible for your trading – both gains and losses.
Crude Oil prices on the rise.Just a quick snapshot showing the 500% + price gain on crude oil from COVID crash in 2020 to March 2022. Over 500% increase.
Given tensions in Ukraine and boycotts of Russia, this bull run is likely to continue.
SBFM - Sunshine Biopharma Doing BIG Things!Always DYOR and understand the dynamics of these OTC stocks (known for pump & dump) but the fundamentals here are what will ultimately drive Sunshine Biopharma to return to it's formerly glorious highs but for now, it's relegated to the fractional levels that we see. On it's face, it looks like a no-brainer . . company shedding debt, increasing earnings (still no real profitability) BUT, a recent patent publication and a litany of amazing solutions in the areas of drug-resistant cancers, COVID-19, etc. But don't take my word for it . . check it out . .
sunshinebiopharma.com
Caveat Emptor - The evil corporate empire will probably try to keep this one squashed and on the DL with massive shorting (if I had to guess) and for several reasons
1. Competition
2. Cancer is big business and people that cure it tend to go away quickly
3. Keep the price low with the help of WS peckerwoods for a cheaper acquisition
Again, I don't render professional investment advice, I just read charts and try to tie the fundamentals into a more complete picture. The Fib channel looks attractive in an uptrend, we just got a nice bump up above the 50/200 EMA and we know what kind of price history this beauty has so it's worth an add. I've got a DCA bag and will LTBH it for either a buyout or until the WS woods drive it to zero, whatever the outcome . . no risk, no reward.
Good luck!
Market crash suspiciously started before the PandemicI am quite sceptic about the official COVID-19 pandemic explanation given the fact that there had been a rehearsal of such pandemic on September 2019 called Event 201, which you can watch a recorded version of on Youtube . This event was held by WHO officials and major important sector actors. This has given a solid base to support the conspiracy thesis. I would not have completely supported such a thesis if I had not run previous research on each of the institutions involved in this Event 201 and the HUGE conflict of interest existing here.
The parties involved both control the media and have enormous power to influence public opinion and hence the market .
The observation of the drop in SPX500 days before the announcement of the pandemic leads me to support the thesis that the pandemic was already a planned event led by pharmaceutics corporations and governments all around the world, not just to make HUGE money profits directly from shorts but also from the many businesses created that were already there getting ready for this event.
This market manipulation is not just a cheating plot, but also one that had tremendous moral and ethical implications.
“If you tell a lie big enough and keep repeating it, people will eventually come to believe it. The lie can be maintained only for such time as the State can shield the people from the political, economic and/or military consequences of the lie. It thus becomes vitally important for the State to use all of its powers to repress dissent, for the truth is the mortal enemy of the lie, and thus by extension, the truth is the greatest enemy of the State.”
~Mein Kampf by Adolf Hitler.
ADGI Potential Neutralizing Activity Against Covid-19 VariantsAdagio Therapeutics announced its lead monoclonal antibody has neutralization activity against the Omicron variant of SARS-CoV-2.
Adagio is evaluating ADG20 in its global Phase 2/3 clinical trials for prevention and treatment of COVID-19.
Adagio is engaging with the FDA regarding protocol updates to its global Phase 2/3 clinical trials.
My price target is the $14.5 resistance.
ARDS Covid-19 Antibody Cocktail | Massive Bullish DivergenceThe chart speaks for itself: ARDS is in a massive bullish divergence at all time low levels from which can explode anytime soon!
Recently, analyst Vernon Bernardino from H.C. Wainwright, who reiterated a buy rating and $19 price target on ARDS , told investors that Aridis Pharmaceuticals Inc 's monoclonal Covid-19 Antibody Cocktail is potentially First-in-Class treatment: "the cocktail binds to the S2 spike protein subunit, which mediates viral cell membrane fusion in SARS-CoV-2 variants and also binds to the omicron variant with no loss in affinity compared to the original Wuhan strain."
Cantor Fitzgerald also said last week that Aridis' pipeline is "underappreciated."
ARDS Pan-Coronavirus Monoclonal Antibody Cocktail Retains Effectiveness Against the Omicron variant, other COVID-19 Variants, SARS, MERS , and the Common Cold Human Coronaviruses.
It provides relevant drug levels for up to 1 year from prophylactic or therapeutic treatment.
Market Cap 27.124Mil
52 Week Range 1.89 - 8.47
I think this might be our 10X stock for 2022.
NOVAVAX Fractal and Symmetric trianglefirst of all thanks for stopping by.. This text below will be posted on every timeframe
Until now, not much was known about Novavax because it was Moderna or Pfizer what was on the news and media, but now NOVAVAX has been in the news and so that's why the chart popped up on my radar .
On the big picture I'm looking at the 2 monthly chart
To remove some noise and get a good idea of the price, I find a DRABW Right Angled Descending Broadening Wedge here, often a Bullish pattern . At the top we see that another support line has been found where the bulls can prepare themself to make an attempt to attack the upper resistance / ATH again. see also in this picture the divergence that has managed to make a considerable run up. Here it is also nice to see how the share price reacts to favorable news for a company like this.
To stay in the even number, we zoom in slightly to the 2W chart.
here we see very nicely how a Bump and Run is rejected on the 0.382 of the fibonacci, the price just looks up the trend channel and from there the bulls make another attack on the resistance line (Lead-in) and with succes. So mirroring the pattern could give an idea for where it could go .. and so we have now ended up in a symmetrical triangle i even think that in an EW count, this could be an Ending diagonal or a correction wave. and after a corrective wave comes another impulse wave (up or down).
Ending with the day chart. zoomed in on the symmetrical triangle.
good to see how the pressure is on the top in the pattern. and the picture is how the situation is. you could even spot a fractal white squares and if it would continue, which means that it could happen again. So keep an eye out and look for supporting within the pattern.
Keep calm, do your own research! trade safe and manage your risk.
*(Disclaimer: This is not financial advice)
NOVAVAX BARR into Symmetric trainglefirst of all thanks for stopping by.. This text below will be posted on every timeframe
Until now, not much was known about Novavax because it was Moderna or Pfizer what was on the news and media, but now NOVAVAX has been in the news and so that's why the chart popped up on my radar .
On the big picture I'm looking at the 2 monthly chart
To remove some noise and get a good idea of the price, I find a DRABW Right Angled Descending Broadening Wedge here, often a Bullish pattern . At the top we see that another support line has been found where the bulls can prepare themself to make an attempt to attack the upper resistance / ATH again. see also in this picture the divergence that has managed to make a considerable run up. Here it is also nice to see how the share price reacts to favorable news for a company like this.
To stay in the even number, we zoom in slightly to the 2W chart.
here we see very nicely how a Bump and Run is rejected on the 0.382 of the fibonacci, the price just looks up the trend channel and from there the bulls make another attack on the resistance line (Lead-in) and with succes. So mirroring the pattern could give an idea for where it could go .. and so we have now ended up in a symmetrical triangle i even think that in an EW count, this could be an Ending diagonal or a correction wave. and after a corrective wave comes another impulse wave (up or down).
Ending with the day chart. zoomed in on the symmetrical triangle.
good to see how the pressure is on the top in the pattern. and the picture is how the situation is. you could even spot a fractal white squares and if it would continue, which means that it could happen again. So keep an eye out and look for supporting within the pattern.
Keep calm, do your own research! trade safe and manage your risk.
*(Disclaimer: This is not financial advice)
NOVAVAX DRABW first of all thanks for stopping by.. This text below will be posted on every timeframe
Until now, not much was known about Novavax because it was Moderna or Pfizer what was on the news and media, but now NOVAVAX has been in the news and so that's why the chart popped up on my radar .
On the big picture I'm looking at the 2 monthly chart
To remove some noise and get a good idea of the price, I find a DRABW Right Angled Descending Broadening Wedge here, often a Bullish pattern . At the top we see that another support line has been found where the bulls can prepare themself to make an attempt to attack the upper resistance / ATH again. see also in this picture the divergence that has managed to make a considerable run up. Here it is also nice to see how the share price reacts to favorable news for a company like this.
To stay in the even number, we zoom in slightly to the 2W chart.
here we see very nicely how a Bump and Run is rejected on the 0.382 of the fibonacci, the price just looks up the trend channel and from there the bulls make another attack on the resistance line (Lead-in) and with succes. So mirroring the pattern could give an idea for where it could go .. and so we have now ended up in a symmetrical triangle i even think that in an EW count, this could be an Ending diagonal or a correction wave. and after a corrective wave comes another impulse wave (up or down).
Ending with the day chart. zoomed in on the symmetrical triangle.
good to see how the pressure is on the top in the pattern. and the picture is how the situation is. you could even spot a fractal white squares and if it would continue, which means that it could happen again. So keep an eye out and look for supporting within the pattern.
Keep calm, do your own research! trade safe and manage your risk.
*(Disclaimer: This is not financial advice)